Metropolis Healthcare Ltd News

Core acquisition adds to Metropolis Healthcare's long-term growth plans

Market share gains in the B2C portfolio are visible and Tier III+ markets are likely to contribute to the patient volume growth guidance

Metropolis Healthcare shares rise 3% after acquiring Core Diagnostics

Shares of diagnostic firm Metropolis Healthcare surged 2.88 per cent at Rs 2,250 per share on the BSE in Tuesday's intraday trade

Metropolis Healthcare to acquire Core Diagnostics for Rs 247 crore

Diagnostic chain Metropolis Healthcare on Monday said it will acquire Core Diagnostics for Rs 247 crore. The company's board has approved the acquisition of 100 per cent stake in Core Diagnostics from its existing shareholder Core Diagnostics (Mauritius) Pvt Ltd, Metropolis Healthcare said in a regulatory filing. Pursuant to the completion of acquisition, Core Diagnostics will become a wholly owned subsidiary of the company, it added. "This strategic acquisition will enhance Metropolis Healthcare's advanced cancer testing capabilities and strengthen its footprint in northern and eastern India," the diagnostic chain said. By leveraging Core Diagnostics' strong relationships with leading cancer specialists and hospitals in these regions, Metropolis aims to expand its market reach and specialised testing offerings, it added. "With approximately 1.4 million new cancer cases and nearly a million deaths annually in India, there is a critical need for advanced cancer testing nationwide.

F&O Cues: Nifty needs to hold above 24,650; check bullish, bearish stocks

Derivatives market update: FIIs reduced longs in index futures marginally on Monday; their index long-short ratio stands at 1:1. Retail traders up long bets.

Patient influx, test volumes raise Metropolis Healthcare's profit by 31%

Commenting on the results, Ameera Shah, Executive Chairperson and Whole-time Director, Metropolis Healthcare, said that the company has consistently achieved high growth in patient volume